Literature DB >> 18004176

Sequential compression devices for treatment of restless legs syndrome.

Arn H Eliasson1, Christopher J Lettieri.   

Abstract

Restless legs syndrome (RLS) is a common disorder that presents with irresistible urges to move the legs and motor restlessness, worsening in the evening. RLS commonly causes insomnia and associated daytime symptoms. Treatment of first choice for RLS is usually medication, but medications are often ineffective or poorly tolerated. An effective nonpharmacologic therapy would be highly desirable. Here we review RLS and its treatment and present data from a pilot study on the effect of a novel treatment for this condition. The objective of this study was to determine the therapeutic effect of pneumatic sequential compression devices (SCDs) on RLS symptoms. We performed an uncontrolled, prospective interventional study using SCDs on a convenience sample of adults reliably diagnosed with RLS. Patients were asked to wear the SCD for an hour each evening before the usual time of onset of restless legs symptoms. Before and after 1-3 months of SCD therapy, patients completed validated questionnaires to assess RLS severity, daytime sleepiness, and impact of RLS on quality of life in the domains of social function, daily task function, sleep quality, and emotional well-being. Compliance with SCD therapy was measured using patient-recorded logs. Of 10 patients (7 women; age range, 37-80 yr; mean age, 56 yr), symptomatic for a mean of 68 months (range, 12-360 mo), 1 could not tolerate wearing the SCD and withdrew from the protocol after 3 days. The remaining 9 patients complied with therapy 58%-100% of nights (mean, 82%). Three patients experienced complete resolution of RLS and 6 patients had improvement of symptoms. Group severity score improved from 24/40 to 8/40 (p = 0.001). Epworth Sleepiness Scale score improved from 12/24 to 8/24 (p = 0.05). Every quality of life score improved: social function from 74% to 96% (p = 0.04), daily task function 63% to 80% (p = 0.05), sleep quality 27% to 63% (p = 0.003), and emotional well-being from 49% to 83% (p = 0.02). In this group of patients, wearing the SCD in the evening for an hour improved symptoms of RLS and improved quality of life, with complete resolution of symptoms in 3 of 10 patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004176     DOI: 10.1097/MD.0b013e31815b1319

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  11 in total

Review 1.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

Review 2.  The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

3.  Effect of sensory stimuli on restless legs syndrome: a randomized crossover study.

Authors:  Anouk D Rozeman; Truus Ottolini; Diana C Grootendorst; Oscar J M Vogels; Roselyne M Rijsman
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

4.  Decreased Symptoms without Augmented Skin Blood Flow in Subjects with RLS/WED after Vibration Treatment.

Authors:  Ulrike H Mitchell; Sterling C Hilton; Erik Hunsaker; Jan Ulfberg
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

5.  Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care.

Authors:  Sara N Davison; Adeera Levin; Alvin H Moss; Vivekanand Jha; Edwina A Brown; Frank Brennan; Fliss E M Murtagh; Saraladevi Naicker; Michael J Germain; Donal J O'Donoghue; Rachael L Morton; Gregorio T Obrador
Journal:  Kidney Int       Date:  2015-04-29       Impact factor: 10.612

Review 6.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Medical devices for restless legs syndrome - clinical utility of the Relaxis pad.

Authors:  Ulrike H Mitchell
Journal:  Ther Clin Risk Manag       Date:  2015-12-03       Impact factor: 2.423

8.  Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome.

Authors:  Ulrike H Mitchell
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-06       Impact factor: 2.570

9.  What patients do to counteract the symptoms of Willis-Ekbom disease (RLS/WED): Effect of gender and severity of illness.

Authors:  Ravi Gupta; Deepak Goel; Sohaib Ahmed; Minakshi Dhar; Vivekananda Lahan
Journal:  Ann Indian Acad Neurol       Date:  2014-10       Impact factor: 1.383

10.  Role of gabapentin enacarbil XR in restless legs syndrome.

Authors:  Sheila Sivam; Brendon J Yee
Journal:  Ther Clin Risk Manag       Date:  2012-05-01       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.